$OSCR

Baltrus Victoria sold $30K of OSCR

Baltrus Victoria (Chief Accounting Officer) sold 958 shares of Oscar Health, Inc. (OSCR) at $31.45 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Baltrus Victoria
Published Sep 8, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
high confidence
Mentioned
$OSCR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The transaction is small relative to total holdings and unlikely to move the stock price.

02

Market read

Limited relevance; primarily of interest to existing shareholders tracking insider activity.

03

What to watch

Potential future 10b5‑1 sales could accumulate; monitor cumulative insider activity.

Relevance 2/10Novelty 3/10Timing: filing today

Background

Form 4 filing discloses a routine insider sale by Oscar Health's CAO under a pre‑arranged plan.

Company-level read

Ticker impact

$OSCRNeutralHigh confidence
Context

Chief Accounting Officer Baltrus Victoria sold 958 shares for $30,129 via a 10b5‑1 plan on 2026‑09‑03.

Expected impact

Minimal impact; likely absorbed without noticeable price movement.

Evidence & confidence

The sale represents less than 0.2% of total shares held and is pre‑arranged, so market reaction is expected to be muted.

Market effects

No material effect on health‑tech sector; typical insider transaction.

None; limited to Oscar Health shareholders.

None; isolated to a single micro‑cap.

Counterpoint

If the insider had a larger stake, the sale could signal concerns, but the size here is negligible.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • Baltrus Victoria

    Chief Accounting Officer of Oscar Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRMed

OSCR Maintained by UBS -- Price Target Raised to $36

UBS maintained a 'Neutral' rating for Oscar Health (OSCR) but raised its price target to $36 from $26. GuruFocus values OSCR at $24.66, suggesting it is 37.9% overvalued at $34.01. The company has a GF Score of 81/100, with strong growth and momentum but concerns over valuation and profitability. Insiders have sold $26.76M in shares over the past three months.

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.